The HIF-1α inhibitors digoxin and 2-ME could not inhibit the expression of NDUFA4L2 in GBM, which may present challenges in the clinical application of NDUFA4L2 targeting in patients with GBM. This evidence concerns the gene HIF1A and glioblastoma.